Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER: T3D-959 in Mild-to-Moderate Alzheimer's Disease
NCT04251182Phase 2Completed
- Sponsor
- T3D Therapeutics
- Start
- Mar 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of t3d-959 in Alzheimer's disease (AD) (4 arms), sponsored by T3D Therapeutics. Primary endpoints: Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 at 28 weeks, Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change at 28 weeks and 1 more. Started Mar 2021; status: completed.
02
Drugs
t3d-959
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04251182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04251182.